Form 4: Crinetics Officer Sells Shares Under 10b5-1 Plan

Crinetics Pharmaceuticals' Chief Medical and Development Officer, Dana Pizzuti, sold 30,000 shares of common stock for $30.43 per share after exercising options.

Summary

• Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, Inc. (CRNX), engaged in transactions on August 22, 2025.
• Exercised options to acquire 30,000 shares of common stock at an exercise price of $16.89 per share.
• Simultaneously sold 30,000 shares of common stock at a volume-weighted average price of $30.43 per share, with sales prices ranging from $30.00 to $30.98 per share.
• The sale was executed automatically pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025.
• Following these transactions, Dana Pizzuti beneficially owns 66,270 shares of common stock and 89,042 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an insider sale can be seen negatively, the transaction was pre-planned under a 10b5-1 plan, which mitigates concerns about opportunistic selling. The officer also realized a significant profit from the option exercise, which is a positive for the individual.

Positives

• The sale was pre-planned under a Rule 10b5-1 trading plan, indicating a structured approach to managing personal holdings rather than an immediate reaction to new information.
• The exercise price of the options ($16.89) is significantly lower than the sale price ($30.43), indicating a profitable transaction for the officer.

Negatives

• An insider sale, even if pre-planned, reduces the officer's direct equity stake in the company, which can sometimes be perceived negatively by investors.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, exercised stock options and sold common stock, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The sale of shares by an officer could be interpreted as a slight negative, but the pre-planned nature under a 10b5-1 plan mitigates concerns. The officer's remaining holdings still align their interests with shareholders.
• Employees: The continued vesting of options is tied to the officer's continued employment, which is a standard incentive structure.

Next Steps

• Remaining stock options subject to the option will continue to vest monthly in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

Key Dates

Recommendation

The filing is a routine insider transaction under a pre-established 10b5-1 plan. It does not provide new fundamental information about Crinetics Pharmaceuticals' operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The officer's profitable exercise and sale are personal financial management and do not signal a change in company prospects.

Keywords

Crinetics Pharmaceuticals, CRNX, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Dana Pizzuti, Chief Medical and Development Officer